Converting From Open To Robotic Prostatectomy: Institutional Impact On Number Of Pelvic Lymph Nodes Retrieved During RALRP
Main Category: Prostate / Prostate CancerAlso Included In: Urology / Nephrology; Cancer / Oncology
Article Date: 06 Jun 2008 - 8:00 PDT
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
ORLANDO, FL (UroToday.com) - Open pelvic lymph node dissection (PLND) remains the gold standard in patients with intermediate and high-risk prostate cancer undergoing radical retropubic prostatectomy (RRP). A group from Rhode Island has adopted robotic-assisted radical prostatectomy. They sought to determine whether robot-assisted laparoscopic PLND yields comparable numbers of lymph nodes compared to open PLND.
After obtaining institutional IRB approval, the open and robotic prostatectomy databases at this single institution were reviewed. Patients undergoing RALRP with robotic PLND over a 1 year period and patients undergoing open radical prostatectomy with open PLND within the last 5 years were identified. The surgical pathology reports were reviewed to determine the number of lymph nodes obtained with each method of PLND. Statistical analysis was performed using Student's t-test.
A total of 80 patients were identified, of whom 28 underwent robot-assisted PLND (2007) and 52 open PLND (2002 to 2007). The mean number of lymph nodes obtained during robotic PLND was 3.2 and the mean number obtained by open PLND was 6.9 (p< 0.001). One patient in each cohort had micro-metastatic disease on PLND; both patients had biopsy-proven Gleason 7 prostate cancer with PSA less than 10. There were no major complications in either group that could be attributed to the PLND.
In this study, robot-assisted laparoscopic PLND yielded fewer lymph nodes compared to open PLND at the time of radical prostatectomy for organ-confined disease. In men with high-risk of lymph node involvement based on preoperative staging, open PLND yields a higher number of lymph nodes compared to robotic PLND in this surgical series and should be considered the gold standard.
Presented by Jennifer Yates, MD, Joseph Renzulli, MD, Harry Iannotti, MD, George E Haleblian, MD, and Gyan Pareek, MD at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our prostate / prostate cancer section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/110155.php>
APA
http://www.medicalnewstoday.com/releases/110155.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




